Clinical, Medical & Diagnostic Products


Expanded partnership launches fi rst digital bone marrow imaging and analysis


Beckman Coulter Diagnostics, a leader in clinical diagnostics, and Scopio Labs, a medtech company specialising in digital cell morphology, have expanded their partnership to include a global distribution agreement for Scopio’s Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. This application, integrated with Scopio’s CE-marked X100 and X100HT platforms, introduces a fully digital workflow for bone marrow aspirate analysis.


Bone marrow aspirate analysis is crucial for diagnosing various hematologic diseases, allowing clinicians to examine the cellular composition and morphology of blood cells. However, traditional methods are manual, time-consuming, and rely heavily on skilled haematopathologists for accurate results. Scopio’s FF-BMA Application revolutionises this process by combining high-resolution Full- Field imaging with an AI-powered decision support system, significantly improving efficiency and accuracy.


The FF-BMA Application also enables remote review of bone marrow smears via secure hospital networks, reducing turnaround times,


promoting collaboration, and facilitating second opinions. “With limited technology available today for bone marrow aspirate analysis, Scopio’s AI-powered solution allows lab scientists to evaluate hundreds of cells more efficiently than manual microscopy,” said Chris Hagen, Senior Vice President at Beckman Coulter. “We are excited to expand our partnership and bring this first-of-its-kind solution to labs worldwide.”


Itai Hayut, CEO of Scopio Labs, echoed this sentiment: “This partnership extension with Beckman Coulter demonstrates our shared commitment to advancing digital transformation in clinical labs. The addition of our digital bone marrow application to Beckman Coulter’s haematology offering highlights the market success of our Full-Field digital cell morphology platform.”


Since 2022, Beckman Coulter and Scopio Labs have worked together to accelerate the adoption of digital cell morphology. In 2023, Beckman Coulter introduced an end-to-end automated haematology solution by integrating its DxH 900 Workcell with Scopio’s X100HT platform for AI-assisted blood smear analysis.


Availability of Scopio’s Full-Field Peripheral Blood Smear™ and Full-Field Bone Marrow Aspirate™ Applications may vary by region. More information online: ilmt.co/PL/bBV2 and ilmt.co/PL/9y27


63330pr@reply-direct.com


New DNA/RNA kit advances haematological cancer research


Thermo Fisher Scientific has launched the Applied Biosystems™ MagMAX™ Sequential DNA/RNA Kit, designed to help clinical and translational researchers accelerate and enhance genomic analysis in haematological cancer research. This innovative kit combines DNA and RNA isolation chemistries into a single solution, simplifying sample extraction for a wide range of molecular applications. By integrating two separate workflows into one sequential process, the MagMAX Sequential DNA/RNA Kit accommodates up to 15,000 white blood cells per microlitre without requiring an additional red blood cell lysis step, making it easier for researchers to streamline their procedures and reduce overall costs.


As haematological cancers such as leukaemia, lymphoma, and myeloma account for about 10% of new cancer cases annually, the need for efficient methods to detect genetic abnormalities in these diseases is growing. The Leukemia & Lymphoma Society highlights the increasing importance of research in these areas. The MagMAX kit allows for the effective isolation of both DNA and RNA from blood or bone marrow samples, providing essential insight into the genetic alterations that drive these cancers.


Kevin Lowitz, Vice President of Sample Preparation at Thermo Fisher Scientific, emphasised the value of this advancement: “When researching blood cancer, it’s crucial for scientists to extract the maximum amount of information from limited sample volumes. This product enables the high-quality, sequential isolation of genomic DNA and total RNA, supporting researchers and clinicians with a solution that improves efficiency and preserves precious samples.”


The MagMAX Sequential DNA/RNA Kit is ideal for specialty labs, large health systems, academic medical centres, and pharmaceutical and biotechnology companies involved in personalised medicine, clinical research, and clinical trials. It offers several key benefits, including the elimination of additional steps like manual RNase treatment when separate DNA and RNA samples are required. Automation of the sequential isolation process helps enhance productivity by streamlining workflows, reducing hands-on time, and speeding up time-to-data. The kit is also flexible and scalable, supporting varying sample volumes and throughput needs, all while maximising efficiency and preserving valuable samples. Its compact design allows for easy storage in diverse lab settings.


More information online: ilmt.co/PL/A7RB 63716pr@reply-direct.com


Study confi rms accuracy of non-invasive test for gastric cancer risk


A clinical study conducted by Homerton University Hospital NHS Foundation Trust, London, has confirmed the diagnostic accuracy of GastroPanel in identifying gastric cancer risk in patients with upper abdominal complaints. The study demonstrated that GastroPanel reliably identifies high-risk patients with over 90% accuracy, supporting early intervention and streamlined patient management. The findings have been published in BMJ Open Gastroenterology.


Designed as a first-line diagnostic tool, GastroPanel provides rapid preliminary assessments for dyspeptic complaints, helping to identify patients who require further specialist evaluation. By reducing the need for costly and invasive endoscopic procedures, it has the potential to alleviate pressure on overstretched NHS endoscopy services.


Jussi Hahtela, CEO of Biohit Oyj, emphasised the significance of early detection, stating: “GastroPanel benefits both patients and healthcare systems by enabling the rapid identification of gastric cancer risk conditions. Patients receive crucial information quickly and non-invasively, while healthcare providers benefit from a more cost-effective alternative to endoscopy.”


Panu Hendolin, Director of R&D at Biohit Oyj, highlighted its alignment with current clinical guidelines: “The British Society of Gastroenterology recommends non-invasive screening for patients at risk of gastric cancer, and GastroPanel meets that need perfectly. The study at Homerton Hospital, involving 324 patients, produced results consistent with previous international studies, further confirming its diagnostic accuracy.”


More information online: ilmt.co/PL/0yGJ 63790pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44